Navigation Links
Pepscan Therapeutics Strengthens Management Team
Date:1/27/2010

LELYSTAD, The Netherlands, January 27 /PRNewswire/ -- Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today named Peter Timmerman, PhD as Chief Technology Officer and Klaus Schwamborn, PhD as Chief Development Officer. These new positions were created after the retirement of its CSO and one of the company founders, Prof. Dr. Rob Meloen.

"Pepscan has recently refocused its R&D program on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides"' said Wim Mol, CEO of the company. "This new focus requires a strengthened presence of both technology and biological development in the management team."

Peter Timmerman is inventor of the CLIPSTM technology and as Head of Chemistry drove the advances in protein mimicking for therapeutic antibodies and peptides at Pepscan. He also holds a chair as Professor in Protein Mimetic Chemistry at the University of Amsterdam (UvA). Timmerman studied in Amsterdam, and obtained his PhD summa cum laude from the University of Twente. In 1995, he was recipient of the Backer prize for the best thesis in Organic Chemistry. Before joining Pepscan he did research at the ETH in Zurich, and was Assistant Professor in Supramolecular Chemistry and Technology at the University of Twente. He is co-author of over 80 scientific articles.

Klaus Schwamborn oversees the entire biology required for the pre-clinical development of therapeutic antibodies and peptides. Before joining Pepscan, he was with Celgene, San Diego USA, in target discovery and developed assays for small molecules in the field of cancer and inflammation. Schwamborn holds a PhD in molecular biology from the University of Gottingen, Germany and completed postdoctoral studies at the Institute Pasteur in Paris, France where he mainly focused on cell signaling and post-translational protein modification. He published in high-impact journals and has in total over 15 year hands-on experience in molecular and cellular biology.

"We are very pleased that Peter Timmerman and Klaus Schwamborn join the management team of Pepscan as successors to Rob Meloen. We thank Rob for the invaluable contributions he made to the development of Pepscan. Without his scientific ingenuity Pepscan would not have been where it is today. We are very pleased that Rob will continue to provide support to Pepscan as a scientific adviser", Mol said.

Notes to the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the Netherlands. The company focuses on protein mimicking technology for the generation of immune therapeutics. It has developed a pipeline of therapeutic vaccine and antibody programs, of which the most advanced is in Phase II clinical testing. Pepscans proprietary CLIPSTM technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs. For more information visit http://www.pepscan.com.

About CLIPSTM technology

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

SOURCE Pepscan Holding N.V.


'/>"/>
SOURCE Pepscan Holding N.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):